[A TRADUIRE] ERYTech Pharma lance un essai clinique de phase II, pour le GRASPA® - le 14 mai 2009
KEY POINTS
Lyon, a leading city in life sciences
BIOPARC LYON, fully dedicated to biotech companies
A 3.4 ha site
40,000 square meters hosting offices and laboratories, a business incubator, technical rooms, a residential complex, support services...
ERYtech Pharma
LAUNCHES A PHASE II CLINICAL TRIAL OF GRASPA
ERYtech Pharma (a biotech company that has been located at Bioparc Lyon® since 2004) has just announced the launch of a Phase II clinical trial of its GRASPA® therapeutic (asparaginase entrapped in human homologous red blood cells), in association with GRAALL (the Lyons-based research network for adult acute lymphoblastic leukemia (ALL)).
ERYtech Pharma hopes that the trial will show an improved prognosis for over-55 patients and a reduction in the side effects related to L-asparaginase's mechanism of action. To achieve this, the company uses a proprietary, patented technology for encapsulation of therapeutic enzymes or other molecules in red blood cells. This technique increases the therapeutic index and favors a decrease in the side effects typically observed with a conventional administration procedure. The end result is a more effective, safer treatment.
According to David Liens MD (Chief Medical Officer at ERYtech Pharma), "the launch of this study at forty or so investigating centers represents a significant milestone in the GRASPA® development program. Our objective is registration in ALL and we are very proud to have set up this project in association with the GRAALL".
For more information, visit the ERYtech Pharma web site
